A new medical imaging approach has shown promising results in detecting cancer lesions in people with renal cell carcinoma, the most common type of kidney cancer. The research suggests that a more targeted PET/CT scan could help doctors understand the extent of the disease more clearly.
The technique focuses on a protein called carbonic anhydrase IX (CAIX), which is commonly found at high levels in clear cell renal cell carcinoma, the most common subtype of the disease.
How the New Imaging Method Works
PET/CT scans combine information about biological activity inside the body with detailed anatomical images. Conventional scans often use a tracer called FDG, which tracks glucose metabolism. However, this approach can have limitations when imaging kidney cancer.
The newer method uses a different tracer designed to target CAIX. Because this protein is strongly expressed in many clear cell kidney cancer cells but is present at much lower levels in normal kidney tissue, it may help suspicious areas stand out more clearly on scans.
Study Reports Higher Lesion Detection
The prospective multicentre study included 68 patients with renal cell carcinoma. Researchers compared the CAIX-targeted PET/CT method with conventional FDG PET/CT.
Across 492 confirmed lesions, the targeted method detected 90.9%, compared with 56.7% for the conventional approach. Among patients with clear cell renal cell carcinoma, detection reached 97.9%, compared with 47.1% using FDG PET/CT.
Patient-level diagnostic accuracy in the clear cell subgroup was also higher with the targeted method: 98.2%, compared with 77.2% for the conventional scan.
Could the Findings Change Treatment Planning?
The researchers reported that the new scan changed disease staging or clinical management in 30.9% of patients, compared with 5.9% using the conventional method. In some cases, it identified disease that had not previously been detected, helping doctors reassess how widely the cancer had spread.
More complete imaging information may help clinicians make decisions about further tests and treatment planning. However, detecting more lesions does not automatically mean that every patient will have better outcomes.
Why More Research Is Needed
The results are encouraging, but the study involved a relatively small group of patients. Larger studies are needed to confirm how reliably the technique performs across different kidney cancer subtypes and in wider clinical settings.
Researchers also need to establish whether the additional information leads to better long-term patient outcomes. The method should therefore be viewed as a promising development in medical imaging, rather than an established replacement for current scanning approaches.
The findings highlight how targeted imaging may help improve cancer assessment in the future, while further research determines its appropriate role in routine care.
